The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1383
Aflibercept (Eylea) for Age-Related Macular Degeneration
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved aflibercept (a flib’ er sept; Eylea – Regeneron) for treatment of neovascular (wet) age-related macular degeneration (AMD).

WET AMD — About 10% of patients with AMD have the neovascular form, characterized by an often rapid decrease in central visual acuity due to newly developed leaky vessels growing from the choroid toward the subretinal space. The principal mediator of neovascularization in wet AMD is thought to be vascular endothelial growth factor (VEGF), which induces angiogenesis and increases vascular permeability and inflammation. Treatment of wet AMD with intravitreal injection of VEGF inhibitors has slowed the course of the disease and in some patients has led to the recovery of lost vision.

VEGF INHIBITORS — The standard VEGF inhibitor for treatment of wet AMD is the recombinant, humanized monoclonal antibody fragment ranibizumab (Lucentis ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Aflibercept (Eylea) for Age-Related Macular Degeneration
Article code: 1383a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian